
Immatics NV (IMTX) Stock Forecast & Price Target
Immatics NV (IMTX) Analyst Ratings
Bulls say
Immatics NV demonstrates a strong fundamental outlook driven by its extensive patent protection for innovative T-cell redirecting immunotherapies, which solidifies its competitive advantage in the oncology sector. The company has shown promising clinical trial results, particularly in cutaneous melanoma and ovarian cancer, with an upgraded launch probability translating to a significant €711.3 million global risk-adjusted sales forecast by 2035. Furthermore, Immatics's compelling clinical data, including a 50% overall response rate and a median progression-free survival that exceeds competitive benchmarks, further strengthens its position in the market.
Bears say
Immatics NV faces significant financial uncertainties due to various risks, including research and development challenges, regulatory hurdles, and the potential emergence of competitors, which may hinder expected product sales. The company is also exposed to potential delays in achieving clinical trial endpoints, which could impede its path to profitability and adversely affect its financial projections. Furthermore, Immatics may need to pursue additional capital through equity financing, raising concerns over share dilution for existing shareholders and negatively impacting the overall financial outlook.
This aggregate rating is based on analysts' research of Immatics NV and is not a guaranteed prediction by Public.com or investment advice.
Immatics NV (IMTX) Analyst Forecast & Price Prediction
Start investing in Immatics NV (IMTX)
Order type
Buy in
Order amount
Est. shares
0 shares